Clinical Trial: A Study of SYS6051 in Subjects With Advanced Solid Tumors

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07591285) titled 'A Study of SYS6051 in Subjects With Advanced Solid Tumors' on May 09.

Brief Summary: This is a multicenter, open-label, dose-escalation and backfill, and cohort-expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of SYS6051 in participants with advanced solid tumors.

Study Start Date: May 12

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: SYS6051

SYS6051 is administered by intravenous infusion every 3 weeks (Q3W). The doses administered for the first and subsequent visits of SYS6051 will be calculated based o...